1 in 8 Americans Now on GLP-1 Drugs: Why Microdosing Tirzepatide May Be the Smarter Path for Sustainable Fat Loss and Muscle Preservation GLP-1 medications have exploded in popularity, with recent surveys showing that about 1 in 8 U.S. adults (roughly 12%) are currently taking a GLP-1 receptor agonist like semaglutide or tirzepatide for weight…
Read more
1 in 8 on GLP-1s: Microdosing Tirzepatide for Better Muscle Retention & Fat Loss
